Citius Pharmaceuticals (CTXR) to Feature Updated Positive Interim Results of i-MSC Study During Poster Presentation at International Society for Cell and Gene Therapy
Get Alerts CTXR Hot Sheet
Join SI Premium – FREE
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it will present a poster at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting, to be held virtually May 26-28, 2021.
Dr. Perenlei Enkhbaatar, Professor and Director of the Translational Intensive Care Unit at The University of Texas Medical Branch, will present a poster describing interim results of a proof-of-concept study evaluating the efficacy and safety of novel induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) in a clinically relevant conscious ovine model of acute lung injury.
Posters will be available starting on May 25, 2021, a pre-conference day dedicated to poster presentations.
Abstract Title: | "Novel Induced-Mesenchymal Stem Cells (i-MSCs) Attenuate Severity of ARDS in Septic Sheep" |
Authors: | K. Hashimoto, N. Bazhanov, P. Enkhbaatar, M. Angel, A. Lader, M. Czuczman, and M. Matthay |
Abstract Number: | 100 |
Date and Time: | May 25, 2021 |
Session I | 12:30 – 2:00 PM EDT |
Session II | 8:00 – 9:30 PM EDT |
"We are encouraged by the positive safety and efficacy signals of i-MSCs, as outlined in the reported interim results of our sheep study. Acute respiratory distress syndrome (ARDS) is a serious and life-threatening condition for which there are no FDA-approved therapies. In future studies, our goal is to increase the sample size and investigate mechanistic pathways. These findings should provide important information in the development of a planned future human clinical trial in ARDS patients. We believe in the potential of our i-MSCs to offer a meaningful option for those suffering from ARDS," stated Dr. Czuczman, Chief Medical Officer and Executive Vice President of Citius Pharmaceuticals, Inc.
The poster will be available to conference attendees via the conference website. The poster will be available on Citius' website once the event commences.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- HOOKIPA Pharma Inc. (HOOK) Receives FDA Clearance of INDA for HB-700
Create E-mail Alert Related Categories
Corporate News, FDARelated Entities
Citi, Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!